Skip to contentE
Enveric Biosciences, Inc.
E
ENVBEnveric Biosciences, Inc. Q2 2023 · 10-Q
Revenue—
Net Income-$6.36M-$6.36MN/M vs Q2 2022 EPS Diluted-$3.04-$3.04N/M vs Q2 2022 Operating Income-$5,755,007N/M Operating Cash Flowderived-$4,465,921N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Enveric Biosciences, Inc. · CIK 890821 · Engraved from SEC EDGAR
Free Cash Flowderived-$4,465,939N/M ended Jun 30, 2023 · filed Aug 11, 2023 · 42 d after period end